Showing results (731-740 of 947) with videos related to

Sort By:
Pageof 95
Virtual Reality|December 19, 2022
Application of virtual reality for peritoneal dialysis exchange learning in patients with end-stage renal disease and cognitive impairmentConnie M S Lee, Kenneth N K Fong, Maggie M Y Mok, et al.
Veterinary Surgery : VS|November 27, 2019
Outcome after surgical and conservative treatments of canine peritoneopericardial diaphragmatic hernia: A multi-institutional study of 128 dogsKeaton R S Morgan, Ameet Singh, Michelle A Giuffrida, et al.
The Science of the Total Environment|July 22, 2023
Uncovering the dominant role of root metabolism in shaping rhizosphere metabolome under drought in tropical rainforest plantsGina A Hildebrand, Linnea K Honeker, Viviana Freire-Zapata, et al.
Neuroscience|May 5, 2007
P2X7-related modulation of pathological nociception in ratsS McGaraughty, K L Chu, M T Namovic, et al.
Human Mutation|March 28, 2008
Exon skipping mutations in collagen VI are common and are predictive for severity and inheritanceA K Lampe, Y Zou, D Sudano, et al.
Nature Communications|April 21, 2023
RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cellsFlorisela Herrejon Chavez, Hanzhi Luo, Paolo Cifani, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 24, 2018
Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trialH Duan, X Chen, Z Li, et al.
Allergy|May 2, 2026
Treatment Dose Increase Versus Co-Medication in Allergic Rhinitis: Systematic Review With Dose-Response Network Meta-AnalysisBernardo Sousa-Pinto, Rafael José Vieira, Sara Gil-Mata, et al.
Cancer|March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptorGlenwood D Goss, Everett E Vokes, Michael S Gordon, et al.
Nature Communications|September 27, 2022
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphomaTatiana Erazo, Chiara M Evans, Daniel Zakheim, et al.
Pageof 95